Valneva Gets Positive Data in Chikungunya Vaccine Trial

By Cecilia Butini Valneva has received positive safety data in a Phase 3 trial studying a vaccine against the mosquito-borne chikungunya virus. Data showed...

Related Keywords

France ,French ,Cecilia Butini , ,Article Normal ,Biotechnology Services ,Pharmaceuticals ,Vaccines ,Healthcare Life Sciences ,Biopharmaceuticals ,Specialized Drugs Medications ,Financial Performance ,Share Price Movement Disruptions ,New Products Services ,Research Development ,Corporate Industrial News ,Products Services ,New Product Service Testing ,Political General News ,Health ,Immunizations ,Medical Conditions ,Vector Borne Zoonotic Diseases ,Infectious Diseases ,Medical Treatments Procedures ,Content Types ,Factiva Filters ,C Amp Ampe Exclusion Filter ,C Amp Ampe Industry News Filter ,Synd ,Valneva Se ,Vla Fr ,Fr Vla ,Fr0004056851 ,Valn ,Us92025y1038 ,Share Price Movement ,Disruptions ,New Products ,Services ,Research ,Development ,Corporate ,Industrial News ,Products ,New Product ,Service Testing ,Political ,General News ,Vector Borne ,Zoonotic Diseases ,Medical Treatments ,Procedures ,Healthcare ,Life Sciences ,Specialized Drugs ,Medications ,